Year: 2024

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ETCAMBRIDGE, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter ended September 30, 2024. “During the third quarter of 2024, our team continued its strong execution as we advanced the dose escalation portions of our Phase 1 clinical trials of XMT-1660 and XMT-2056, made further progress in our collaborations and maintained the strength of our...

2024 Fourth Quarter Revenue Guidance Completes Year of Quarter Over Quarter Growth Announces Additional SiPho and SiGe Capacity Build Out, Strategically Serving Expansive Customer Demand MIGDAL HAEMEK, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) — Tower Semiconductor (NASDAQ: TSEM & TASE: TSEM) reports today its results for the third quarter ended September 30, 2024. Third Quarter of 2024 Results Overview Revenue for the third quarter of 2024 was $371 million as compared to $351 million for the second quarter of 2024, representing 6% quarter over quarter growth. Revenue for the third quarter of 2023 was $358 million. Gross profit for the third quarter of 2024 was $93 million as compared to $87 million for the second quarter of 2024 and for the third quarter of 2023. Operating profit for the third quarter of 2024 was $56 million...

Business performance strong, results as expected MISSISSAUGA, Ontario, Nov. 13, 2024 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q3 2024 financial and operational results of KPT and Kruger Products Inc. (Kruger Products). Kruger Products is Canada’s leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and BonterraTM) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 12.6% interest in Kruger Products. Kruger Products Q3 2024 Business and Financial HighlightsRevenue was $521.1 million in Q3 2024 compared to $473.4 million in Q3 2023, an increase of $47.7 million or 10.1%. Adjusted EBITDA1 was $65.7...

Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) — Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company’s Board of Directors, working with a strategic advisor, has initiated a process to evaluate a broad...

Healthy Core Business Operations – Year-to-Date Cut Herbs Sales Up 55% and Pulp Sales Up; Momentum Expected to Continue into 2025 Conference Call to Be Held Today at 8:00 am ET BELVIDERE, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, today provided a business update and reported financial results for the three months ended September 30, 2024. Jim Kras, Chief Executive Officer of Edible Garden, commented, ” We are pleased to report another strong quarter. Earlier this year, we made a strategic shift away from lower margin floral and lettuce products. This decision continues to pay dividends, highlighted by a $687,000 increase in gross...

Third quarter 2024 GAAP net income of $1.4 million or $0.06 per basic weighted average common share and Distributable Earnings(1)  of $7.2 million or $0.35 per basic weighted average common share Paid first post-spin dividend of $0.33 per common share for third quarter 2024 WEST PALM BEACH, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) — Advanced Flower Capital Inc. (f/k/a AFC Gamma, Inc.) (NASDAQ:AFCG) (“Advanced Flower Capital”, “AFC” or the “Company”) today announced its results for the quarter ended September 30, 2024. AFC reported generally accepted accounting principles (“GAAP”) net income of $1.4 million or $0.06 per basic weighted average common share and Distributable Earnings of $7.2 million or $0.35 per basic weighted average common share for the third quarter of 2024. “We are pleased with the strong quarter, driven by our continued...

Revenues Increased by 17% Year-over-Year GAAP Operating Income of $6.7 Million Adjusted EBITDA of $10.7 Million PETAH TIKVA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today reported its results for the third quarter, ended September 30, 2024. Third Quarter 2024 Financial HighlightsRevenues of $74.6 million, up 17% compared with $63.9 million in Q3 2023; GAAP operating income of $6.7 million, compared with $12.7 million in Q3 2023;GAAP operating income includes other income, net, of $1.3 million. Q3 2023 GAAP operating income included other income, net, of $7.4 million;Non-GAAP operating income of $8.3 million, up 36% compared with $6.1 million in Q3 2023; GAAP net income of $6.8 million,...

– CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD – – On track to report topline results from Phase 2 SHIMMER study investigating CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB) by end of 2024 – PURCHASE, N.Y., Nov. 13, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”) today reported financial results for the third quarter ended September 30, 2024, and provided a business update. “In the third quarter and recent weeks Cognition Therapeutics achieved one of the most important milestones in its history as the...

TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Golconda Gold Ltd. (“Golconda Gold” or the “Company”) (TSX-V: GG; OTCQB: GGGOF) is pleased to announce the release of its financial results for the three and nine months ended September 30, 2024. A copy of the unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2024, prepared in accordance with International Financial Reporting Standards, and the corresponding management’s discussion and analysis (the “MD&A”), are available under the Company’s profile on www.sedarplus.ca. All references to “$” in this press release refer to United States dollars. Third Quarter 2024 (“Q3 2024”) Highlights:mined 28,101 tonnes of ore from its Galaxy and Princeton ore bodies, with an average grade of 3.18 grammes per tonne (g/t) compared to...

Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial; initial clinical data including safety and biodistribution on track for late Q1 / early Q2 2025 Appointed Tolga Tanguler to Board of Directors, an accomplished...